NASDAQ · Health care

BioNTech SE (BNTX)

BioNTech SE reported revenue of €2.9B in fiscal 2025, up 4.3% from a year earlier. It posted a net loss of €1.1B. Operating cash flow minus capital spending left €280.9M of free cash flow in fiscal 2025. At December 31, 2025 it held €7.7B in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on July 30, 2026.

Watch BNTX in 60 seconds

Price

$87.51

0.00% on the day · November 9, 2026

52-week range $79.52 to $124.00

Market cap

$22B

Revenue (FY2025)

€2.9B

+4.3% year on year

Net margin

-39.6%

Key facts about BioNTech SE

Net worth: BioNTech SE has a market value (market cap) of $22B at the latest share price, and shareholders' equity of €19.2B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was €2.9B (+4.3% year on year), with a net loss of €1.1B.
Cash flow: In fiscal 2025 operations brought in €456M of cash; after €175.1M of capital spending, free cash flow was €280.9M.
Latest report: The latest periodic report (annual report (foreign issuer, amended), 20-F/A) was filed with the SEC on July 30, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR

What BioNTech SE does

BioNTech SE is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BNTX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	€2.9B	-€1.4B	-€1.1B	-€4.70	€280.9M
2024	€2.8B	-€1.3B	-€665.3M	-€2.77	-€78.8M
2023	€3.8B	€690.4M	€930.3M	€3.83	€5.1B
2022	€17.3B	€12.6B	€9.4B	€37.77	€13.2B
2021	€19B	€15.3B	€10.3B	€39.63	€762.2M
2020	€482.3M	-€82.4M	€15.2M	€0.06	-€79.5M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where BNTX ranks in Health care

Revenue growth+4.3%

#359 of 532 in Health care · Bottom 33%

Net margin-39.6%

#378 of 544 in Health care · Bottom 31%

Free cash flow margin9.8%

#129 of 490 in Health care · Top 26%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

Fiscal year	Per share	Paid out	Of profit
2024	n/a	€0	n/a
2023	n/a	€0	0%
2022	n/a	€484.3M	5%
2021	n/a	€0	0%
2020	n/a	€0	0%

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What BioNTech SE has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 3, 2026
Foreign issuer update 6-K
November 3, 2026
Foreign issuer update 6-K
October 26, 2026
Foreign issuer update 6-K
October 26, 2026
Foreign issuer update 6-K
October 22, 2026
Foreign issuer update 6-K
October 19, 2026
Foreign issuer update 6-K
October 13, 2026
Foreign issuer update 6-K
September 18, 2026
Foreign issuer update 6-K
September 14, 2026
Foreign issuer update 6-K
August 28, 2026
Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 9, 2026. Insider transactions on SEC

Insider trades

What the people running BioNTech SE did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $84.2M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)

last 90 days

Sold

$84.2M

last 90 days

Net sold

858,209

$84.2M

Date	Insider	What	Shares	Price	Value	Filing
October 9, 2026	Sahin UgurChief Executive Officer, 10% owner	Soldpre-planned (10b5-1)	36,209	$95.37	$3.5M	Form 4
October 8, 2026	Sahin UgurChief Executive Officer, 10% owner	Soldpre-planned (10b5-1)	27,000	$92.31	$2.5M	Form 4
October 7, 2026	Sahin UgurChief Executive Officer, 10% owner	Soldpre-planned (10b5-1)	24,000	$95.86	$2.3M	Form 4
October 6, 2026	Sahin UgurChief Executive Officer, 10% owner	Soldpre-planned (10b5-1)	21,000	$96.81	$2M	Form 4
October 5, 2026	Sahin UgurChief Executive Officer, 10% owner	Soldpre-planned (10b5-1)	72,000	$97.23	$7M	Form 4
October 2, 2026	Sahin UgurChief Executive Officer, 10% owner	Soldpre-planned (10b5-1)	17,000	$96.72	$1.6M	Form 4
October 1, 2026	Sahin UgurChief Executive Officer, 10% owner	Soldpre-planned (10b5-1)	17,000	$97.46	$1.7M	Form 4
September 30, 2026	Sahin UgurChief Executive Officer, 10% owner	Soldpre-planned (10b5-1)	32,000	$98.12	$3.1M	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BNTX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Athos KG13G, passive with 2 related filers	40.2%	101,702,378	May 14, 2026
Prof. Ugur Sahin, M.D.13G, passive with 1 related filers	17.6%	42,178,034	May 13, 2025
Ugur Sahin13G, passive with 1 related filers	15.8%	40,076,320	May 15, 2026
BioNTech SE13D, may seek influence	12.5%	33,333,333	February 21, 2024

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 282 managers reported a position.

Holder	Shares	Value	Change on quarter
Fmr LLC	7,571,805	$704.6M	+1,862,565
Primecap Management Co	3,772,031	$351M	-21,680
Dodge & Cox	3,677,591	$342.2M	+800
Flossbach Von Storch SE	2,226,138	$207.1M	-1,454,177
BlackRock, Inc.	1,854,966	$172.6M	+196,813
Temasek Holdings (Private) Ltd	1,506,027	$140.1M	0
Bnp Paribas Financial Markets	1,319,517	$122.8M	-332,272
Logos Global Management LP	1,015,000	$94.4M	new
GSK plc	889,824	$82.8M	0
Assenagon Asset Management S.A.	846,526	$78.8M	new
First Trust Advisors LP	791,469	$73.6M	-48,522
Davern Capital Partners, LP	754,550	$70.2M	+449,495
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	744,200	$69.2M	-39,795
Massachusetts Financial Services Co	677,708	$63.1M	+7,194
Long Focus Capital Management, LLC	624,000	$58.1M	0
Baillie Gifford & Co	592,380	$55.1M	-290,192
Goldman Sachs Group Inc	589,903	$54.9M	+493,074
Victory Capital Management Inc	539,787	$50.2M	+62,864
Franklin Resources Inc	539,593	$50.2M	+154,967
Candriam S.C.A.	497,530	$46.3M	+9,163

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 399,387 shares in total, about $35M at the last price.

Holder	Shares	As of
Poetting SierkChief Operating Officer	399,387399,387 held indirectly	April 22, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BNTX

What does BioNTech SE do?

BioNTech SE is a company in the Health care sector, listed on NASDAQ as BNTX. Its shares trade on NASDAQ under the ticker BNTX.

What is BioNTech SE's net worth?

BioNTech SE has a market value (market cap) of $22B at the latest share price, and shareholders' equity of €19.2B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is BioNTech SE profitable?

No. In fiscal 2025 it reported a net loss of €1.1B on revenue of €2.9B.

How much revenue does BioNTech SE make?

In fiscal 2025 BioNTech SE reported revenue of €2.9B. That is 4.3% more than a year earlier.

When did BioNTech SE last report?

Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on July 30, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 3, 2026.

Similar companies

MRNA

Moderna, Inc.

NBIX

Neurocrine Biosciences Inc

Halozyme Therapeutics, Inc.

TECH

BIO-TECHNE Corp

Compare BNTX with

Compare BNTX with any company

Follow BNTX

Get an email when BioNTech SE files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values BioNTech SE tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.